BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 36369389)

  • 1. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
    Fitzgerald KN; Motzer RJ; Lee CH
    Nat Rev Urol; 2023 Mar; 20(3):179-193. PubMed ID: 36369389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
    Serzan M; Atkins MB
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
    Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
    Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments.
    Boyle JJ; Pfail JL; Lichtbroun BJ; Singer EA
    JCO Precis Oncol; 2023 Feb; 7():e2200407. PubMed ID: 36724413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy in renal cell carcinoma.
    Gul A; Rini BI
    Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative systemic therapy in renal cell carcinoma.
    MacPhail C; Wood LA; Thana M
    Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
    Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
    Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Pradere B; Schuettfort VM; Mostafaei H; Katayama S; Grossmann NС; Rajwa P; Resch I; Enikeev D; Karakiewicz PI; Shariat SF; Schmidinger M
    Urol Oncol; 2021 Nov; 39(11):764-773. PubMed ID: 34400065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
    Cetin B; Wabl CA; Gumusay O
    Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
    Zouein J; Naim N; Kourie HR
    Immunotherapy; 2023 Feb; 15(2):93-100. PubMed ID: 36601860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.
    Ingels A; Campi R; Capitanio U; Amparore D; Bertolo R; Carbonara U; Erdem S; Kara Ö; Klatte T; Kriegmair MC; Marchioni M; Mir MC; Ouzaïd I; Pavan N; Pecoraro A; Roussel E; de la Taille A
    Nat Rev Urol; 2022 Jul; 19(7):391-418. PubMed ID: 35546184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
    Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
    Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Martinez Chanza N; Tripathi A; Harshman LC
    Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.